BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BEBT-260’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BEBT-260 overview
BEBT-260 is under development for the treatment of solid tumors including ovarian cancer, breast cancer, non-small cell lung cancer, small-cell lung cancer, head and neck squamous cell carcinoma, colon cancer, cervical cancer, hilar cancer, anal canal cancer, pancreatic cancer, triple-negative breast cancer (TNBC), penile cancer, vulvar cancer, gastric cancer and kidney cancer. The therapeutic candidate acts by targeting Serine/Threonine Protein Kinase Chk1 checkpoint kinase 1 (Chk 1). It is administered through intravenous route.
Guangzhou BeBetter Medicine Technology overview
Guangzhou BeBetter Medicine Technology (Guangzhou BeBetter Medicine Technology Co) that involves in developing oral biologics to treat autoimmune, inflammatory and metabolic diseases. The company is headquartered in Changsha, China.
For a complete picture of BEBT-260’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
